Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delipidated bacillus calmette-guérin vaccine
- Development stage
- Preclinical
- Lead developer
- Texas Biomedical Research Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
Delipidated bacillus calmette-guérin (dBCG) is a modified version of the live attenuated *Mycobacterium bovis* BCG vaccine. It is produced by treating the bacteria with petroleum ether to selectively remove surface-exposed inflammatory lipids, such as trehalose dimycolate (TDM), phenolic glycolipids (PGL), and phthiocerol dimycocerosates (PDIMs), while maintaining bacterial viability. This modification is specifically designed to reduce the excessive inflammatory response and lung immunopathology associated with traditional BCG when administered via the pulmonary route. Research indicates that pulmonary delivery of dBCG enhances protective immunity against *Mycobacterium tuberculosis* by promoting IL-17A-mediated responses and inducing robust local T-cell memory, potentially offering a more effective strategy for preventing pulmonary tuberculosis than standard intradermal vaccination.
- Other names
- delipidated Mycobacterium bovis BCG vaccinepetroleum ether-extracted BCG
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on delipidated bacillus calmette-guérin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delipidated bacillus calmette-guérin vaccine.